![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Horizon and Arrowhead to Develop RNAi Therapeutic for Gout
Horizon and Arrowhead to Develop RNAi Therapeutic for Gout
![Signing](https://www.fdanews.com/ext/resources/test/Drug-Images/signing.jpg?t=1620076341&width=430)
June 23, 2021
Horizon Therapeutics has entered into a $700 million development and licensing deal with Arrowhead Pharmaceuticals for Arrowhead’s investigational RNA interference (RNAi) treatment for gout.
The global collaboration and license agreement is for ARO-XDH, a drug that works by interfering with messenger-RNA to turn off the production of specific genes.
Under the agreement, Horizon will have a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization, while Arrowhead will receive $40 million as an upfront payment and up to $660 million in milestone payments along with royalties on sales.
Upcoming Events
-
21Oct